News

In an interview with Targeted Oncology, Thomas M. Habermann, MD, reflects on the advancements he has observed in the treatment paradigm for lymphomas.

The FDA has granted a Breakthrough Therapy designation to magrolimab as treatment of patients with newly diagnosed myelodysplastic syndrome.

During a presentation at the 2020 Society of Hematologic Oncology Virtual Annual Meeting, Andrzej Jakubowiak, MD, PhD, reviewed clinical trials of CAR T-cell therapy in multiple myeloma and the emergence of CAR T cells against SMALF7, GPRC5D, and CD229.

The combination of ibrutinib and venetoclax will be tested as frontline therapy in previously untreated patients with mantle cell lymphoma as part of the 3-part phase 3 SYMPATICO trial.

In an interview with Targeted Oncology, Prithviraj Bose, MD, discussed the disease outcomes for patients with essential thrombocythemia, as well as the unmet needs and therapeutic strategies available in this space.

Regorafenib demonstrated a tolerable safety profile as treatment of patients with unresectable hepatocellular carcinoma in the real world, according to results from the ongoing prospective observational REFINE study.

A Fast Track designation has been granted by the FDA to EPI-7386, a selective androgen receptor inhibitor, which is a potential treatment for adult patients with metastatic castration-resistant prostate cancer that is resistant to standard-of-care therapy.

Binimetinib demonstrated activity as treatment of patients with low-grade serous ovarian carcinomas in the randomized phase 3 MILO/ENGOT-ov11 study.

Nathan A. Pennell, MD, PhD, discussed the case of 66-year-old patient with EGFR-mutant non–small cell lung cancer, during a virtual Case Based Peer Perspectives event.

Compared to other racial and ethnic groups, Black patients were the least likely to receive chemotherapy or surgical resection for colorectal liver metastases and experienced worse survival, according to a published research paper.

Acalabrutinib sustained superiority in terms of extended progression-free survival with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia, which was inclusive of patients with high-risk features, results from the phase 3 ASCEND trial (NCT02970318) show.

The FDA has granted a Breakthrough Therapy designation to toripalimab for the treatment of patients with nasopharyngeal carcinoma, marking the first anti-PD-1 antibody from China to receive this designation.

Targeted Oncology reviews trending news online for the week of September 11, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

A supplemental Biologics License Application has been submitted to the FDA seeking approval of a subcutaneous formulation of daratumumab with hyaluronidase-fihj as treatment of patients with light chain amyloidosis.

A higher percentage of patients with nonmetastatic castration-resistant prostate cancer were alive at 3 years on treatment with darolutamide compare with placebo, according to published results from the final analysis of the phase 3 ARAMIS clinical trial.

A Breakthrough Therapy designation was granted to plinabulin as treatment of chemotherapy-induced neutropenia from both the FDA in the United States and China’s Center for Drug Evaluation of the National Medical Products Administration.

The efficacy of ixazomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone plus placebo was shown in the phase 3 TOURMALINE-MM2 trial for patients with newly diagnosed multiple myeloma who were not eligible for autologous stem cell transplant, according to a press release from Takeda.

JAK inhibitors continue to make a splash in the treatment landscape of MPNs and are be evaluated in multiple clinical trials, and the advancement of these agents should be recognized in honor of MPN Awareness Day.

Targeted Oncology was joined by Kami J. Maddocks, MD, for the discussion of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma in a recent tweet chat.

CLR 131 induced a clinically meaningful objective response rate of 40% as treatment of patients with multiple myeloma who are triple class refractory in the phase 2 CLOVER-1 clinical trial.

In an interview with Targeted Oncology, Alan P. Z. Skarbnik, MD, discussed the current therapeutic strategies for treating patients with FL.

The combination of atezolizumab and paclitaxel was not effective for the treatment of patients with treatment-naïve inoperable locally advanced or metastatic triple-negative breast cancer, according to an FDA alert.

The combination of nivolumab plus ipilimumab demonstrated long-term survival and response benefits as treatment of poor- to intermediate-risk patients with advanced renal cell carcinoma with sarcomatoid features compared with sunitinib, according to published results from the phase 3 CheckMate 214 clinical trial.

The FDA granted an Orphan Drug designation to KNO46 for the treatment of thymic epithelial tumors.

A novel Bcl-2 inhibitor, APG-2575, has been granted an Orphan Drug designation by the FDA for the treatment of patients with chronic lymphocytic leukemia.

Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.

In an interview with Targeted Oncology Guillermo Garcia-Manero, MD, discussed the key findings from the QUAZAR AML-001 study and the importance of the FDA approval of CC-486 in post-remission acute myeloid leukemia.

The FDA has granted a priority review to pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer as well as for patients with RET fusion–positive thyroid cancer.

The FDA has approved pralsetinib for the treatment of adult patients with metastatic RET fusion–positive non–small cell lung cancer, as detected by an FDA-approved test.

The FDA has accepted a supplemental Biologics License Application for axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma after 2 or more prior lines of systemic therapy.